Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 1.00 |
| ▸ | HTR2A | P28223 | 10/20 | 1.00 |
| ▸ | HTR2B | P41595 | 9/20 | 1.00 |
| ▸ | PNMT | P11086 | 1/20 | 0.77 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.50 |
| ▸ | MLNR | O43193 | 1/20 | 0.49 |
| ▸ | F7 | P08709 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29676733 | 1.00 | HTR2C (1.00) | HTR2CHTR2AHTR2BPNMTADRB1 | |
| Hydrochloric Acid SCHEMBL5767968 | 0.98 | HTR2C (0.96) | HTR2CHTR2AHTR2BPNMTADRB1 | |
| SCHEMBL532012 | 0.87 | PNMT (0.85) | HTR2CHTR2AHTR2BPNMTADRB1 | |
| SCHEMBL29587836 | 0.87 | PNMT (1.00) | HTR2CHTR2AHTR2BPNMTADRA2A | |
| SCHEMBL329775 | 0.87 | PNMT (1.00) | HTR2CHTR2AHTR2BPNMTADRA2A | |
| Hydrochloric Acid SCHEMBL1124954 | 0.85 | PNMT (0.96) | HTR2CHTR2AHTR2BPNMTADRA2A | |
| Hydrochloric Acid SCHEMBL947776 | 0.85 | PNMT (0.81) | HTR2CHTR2AHTR2BPNMTADRB1 | |
| SCHEMBL15962624 | 0.83 | — | — | |
| Ammonia Solution, Strong SCHEMBL10465265 | 0.80 | HTR2A (0.67) | HTR2CHTR2AHTR2BPNMTF7 | |
| SCHEMBL31317921 | 0.79 | HTR2C (0.65) | HTR2CHTR2AHTR2BPNMTADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226110-A1 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | APNIMED, INC. (DELAWARE) | 2024-07-11 | — | — | US | claimed |
| WO-2023278597-A1 | 5-HT2C AGONISTS FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | APNIMED, INC. (DELAWARE) (US) | 2023-01-05 | — | — | WO | claimed |
| WO-2014195695-A1 | THERAPEUTIC COMBINATIONS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2014-12-11 | — | — | WO | claimed |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-11-07 | — | — | US | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20240226110-A1 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | APNIMED, INC. (DELAWARE) | 2024-07-11 | — | — | US | disclosed |
| US-20240174631-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | RECOVERY THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-26 | — | — | US | disclosed |
| EP-4291177-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | Recovery Therapeutics, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-117157069-A | Compounds, compositions and methods for modulating FGF activity | 康复治疗公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20030149024-A1 | Therapeutic compounds | PHARMACIA & UPJOHN COMPANY | 2003-08-07 | — | — | US | disclosed |
| US-6218385-B1 | FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS | HOFFMANN-LA ROCHE INC. | 2001-04-17 | — | — | US | disclosed |
| EP-1074549-A2 | Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors | F. HOFFMANN-LA ROCHE AG (CH) | 2001-02-07 | — | — | EP | disclosed |
| EP-0513174-B1 | 4,5-CYCLOALKANO-3-BENZAZEPIN-7-OL-DERIVATIVES AND THEIR USE | SCHERING CORP (US) | 1995-08-16 | — | — | EP | disclosed |
| US-5362728-A | Psychoses, analgesics | SCHERING CORPORATION (US) | 1994-11-08 | — | — | US | disclosed |
| EP-0513174-A1 | 4,5-CYCLOALKANO-3-BENZAZEPIN-7-OL-DERIVATIVES AND THEIR USE. | SCHERING CORP (US) | 1992-11-19 | — | — | EP | disclosed |
| WO-1991011437-A1 | 4,5-CYCLOALKANO-3-BENZAZEPIN-7-OL-DERIVATIVES AND THEIR USE | SCHERING CORPORATION (US) | 1991-08-08 | — | — | WO | disclosed |
| EP-0080012-A1 | 6-Chloro-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its acid addition salts and its use as an intermediate | SMITHKLINE BECKMAN CORPORATION (US) | 1983-06-01 | — | — | EP | disclosed |
| US-3716639-A | ANOREXIGENIC TETRAHYDROBENZAZEPINES | CIBA GEIGY CORP | 1973-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | HTR2C 2712/4885HTR2A 3716/4885HTR2B 3566/4885 |
| US-20240174631-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | FGF1, FGF2, FGFR1 | HTR2C 1517/4885HTR2A 1239/4885HTR2B 2151/4885 |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | HTR2C 2742/4885HTR2A 3719/4885HTR2B 3587/4885 |
| US-20030149024-A1 | Therapeutic compounds | REN, HMGCR, RPS4X | HTR2C 2608/4885HTR2A 3432/4885HTR2B 2968/4885 |
| US-20240226110-A1 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | HTR2C, HTR5A, HTR1A | HTR2C 1/4885HTR2A 5/4885HTR2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.